Biogen and Bio-Thera Report Results of BAT1806 (biosimilar, tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

 Biogen and Bio-Thera Report Results of BAT1806 (biosimilar, tocilizumab) in P-III Study for Moderate to Severe Rheumatoid Arthritis

Biogen’s BIIB111 Fails to Meet its Primary Endpoint in P-III STAR Study for Choroideremia

Shots:

  • The P-III study involves assesing the safety, efficacy, immunogenicity & PK of BAT1806 vs Actemra/RoActemra (tocilizumab) in 621 patients with the mod. to sev. RA with inadequate response to methotrexate
  • The study met its 1EPs that demonstrated equivalent efficacy and comparable safety profile to the Actemra/RoActemra. The 1EP of the study was ACR20
  • Biogen has exclusive regulatory, manufacturing, and commercial rights of BAT1806 in all countries excluding China (include Hong Kong, Macau, and Taiwan). In 2021, companies collaborated under which Bio-Thera will receive $30M payment following the achievement of P-III satisfactory results and is eligible for milestones along with royalties

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Stat News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post